[go: up one dir, main page]

AU3348700A - Compounds which inhibit leukocyte adhesion mediated by vla-4 - Google Patents

Compounds which inhibit leukocyte adhesion mediated by vla-4

Info

Publication number
AU3348700A
AU3348700A AU33487/00A AU3348700A AU3348700A AU 3348700 A AU3348700 A AU 3348700A AU 33487/00 A AU33487/00 A AU 33487/00A AU 3348700 A AU3348700 A AU 3348700A AU 3348700 A AU3348700 A AU 3348700A
Authority
AU
Australia
Prior art keywords
vla
compounds
leukocyte adhesion
adhesion mediated
inhibit leukocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33487/00A
Inventor
Susan Ashwell
Reinhardt Bernhard Baudy
Michael A. Pleiss
Dimitrios Sarantakis
Eugene D. Thorsett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC, American Home Products Corp filed Critical Elan Pharmaceuticals LLC
Publication of AU3348700A publication Critical patent/AU3348700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
AU33487/00A 1999-01-25 2000-01-21 Compounds which inhibit leukocyte adhesion mediated by vla-4 Abandoned AU3348700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23747399A 1999-01-25 1999-01-25
US09237473 1999-01-25
PCT/US2000/001603 WO2000043415A1 (en) 1999-01-25 2000-01-21 Compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (1)

Publication Number Publication Date
AU3348700A true AU3348700A (en) 2000-08-07

Family

ID=22893870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33487/00A Abandoned AU3348700A (en) 1999-01-25 2000-01-21 Compounds which inhibit leukocyte adhesion mediated by vla-4

Country Status (9)

Country Link
EP (1) EP1150997A1 (en)
JP (1) JP2002539080A (en)
CN (1) CN1185250C (en)
AR (1) AR029611A1 (en)
AU (1) AU3348700A (en)
CA (1) CA2359114A1 (en)
HK (1) HK1044549B (en)
MX (1) MXPA01007394A (en)
WO (1) WO2000043415A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200617B1 (en) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. DERIVATIVES OF UREA AS ANTAGONISTS OF INTEGRINAS ALPHA 4.
JP2005022976A (en) * 2001-07-18 2005-01-27 Ajinomoto Co Inc Carboxylic acid derivative
EP1450901A4 (en) 2001-12-10 2005-05-25 Bristol Myers Squibb Co (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
MXPA05007843A (en) * 2003-01-24 2005-10-18 Elan Pharm Inc Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents.
CA2522084A1 (en) * 2003-04-10 2004-10-28 Amgen Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
JP2019530678A (en) * 2016-09-18 2019-10-24 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド YAP1 inhibitor targeting the interaction of YAP1 with OCT4
PE20211450A1 (en) 2018-03-14 2021-08-05 H Lee Moffitt Cancer Ct & Res YAP1 INHIBITORS DIRECTING THE INTERACTION OF YAP1 WITH OCT4

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1102316A (en) * 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
FR2679903B1 (en) * 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
AU1354292A (en) * 1991-03-18 1992-10-21 Pentapharm Ag Parasubstituted phenylalanine derivates
DE69530392D1 (en) * 1994-07-11 2003-05-22 Athena Neurosciences Inc INHIBITORS OF LEUKOCYTE ADHESION
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc Heterocyclic amides as cell adhesion inhibitors
WO1998053817A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
NZ502582A (en) * 1997-07-31 2002-07-26 American Home Prod Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4

Also Published As

Publication number Publication date
WO2000043415A1 (en) 2000-07-27
CN1340058A (en) 2002-03-13
CN1185250C (en) 2005-01-19
EP1150997A1 (en) 2001-11-07
JP2002539080A (en) 2002-11-19
HK1044549A1 (en) 2002-10-25
CA2359114A1 (en) 2000-07-27
AR029611A1 (en) 2003-07-10
MXPA01007394A (en) 2002-04-09
HK1044549B (en) 2005-05-27

Similar Documents

Publication Publication Date Title
AU2623900A (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
IL133641A0 (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
ZA986834B (en) Compounds which inhibit leukocyte adhesion mediated by VLA-4.
HUP0002680A3 (en) Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
IL133638A0 (en) 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
IL133636A0 (en) Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4
ZA986827B (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4.
AU3348800A (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
IL133637A0 (en) Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
AU1278701A (en) Novel compounds
AU2408300A (en) Novel compounds
AUPQ441499A0 (en) Novel compound
AU2623800A (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
AU3348700A (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
AU6517800A (en) Ntr3, a member of the tnf-receptor supergene family
AU4132200A (en) Novel compounds
AU2109700A (en) Novel compounds
HK1026218A (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
HK1026219A (en) Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
AU4156800A (en) Novel compounds
AU2288900A (en) Novel compounds
HK1026424A (en) Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4
HK1026217A (en) 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
HK1025976A (en) Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
HK1026435A (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase